BioMedPartners
Overview
BioMedPartners is a Swiss venture capital firm specializing in early- to mid-stage life science and healthcare investments across Europe.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Alentis Therapeutics | Jun 2021 | Series B | - |
| Inotrem | Feb 2020 | Series B | Co-investor |
| Aleva Neurotherapeutics | Dec 2019 | Series E | Co-investor |
| T-CURX GmbH | Dec 2025 | Series A | Lead |
| Dimericon Therapeutics | May 2023 | Seed | Lead |
For institutional investors. Book with your work email.
Key People
Markus Hosang
General Partner
Thomas Möller
Managing General Partner
Stefan Fäs
CFO & Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is BioMedPartners based?
BioMedPartners is headquartered in Basel, Switzerland.
When was BioMedPartners founded?
BioMedPartners was founded in 2002.
How many portfolio companies does BioMedPartners have?
BioMedPartners has 19 portfolio companies in Caplight's dataset.
What are some companies in BioMedPartners's portfolio?
Portfolio companies visible on Caplight include Alentis Therapeutics, Inotrem, Aleva Neurotherapeutics, T-CURX GmbH, Dimericon Therapeutics.
What was BioMedPartners's most recent investment shown here?
BioMedPartners's most recent investment in this portfolio sample was in T-CURX GmbH in 2025.
What sectors does BioMedPartners focus on?
BioMedPartners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech.
What company stages does BioMedPartners focus on?
BioMedPartners typically invests at the MultiStage stage.
What is BioMedPartners's AUM?
BioMedPartners's assets under management are estimated between $385.0M and $500.0M.